YUHSpace

BROWSE

Export
263 423

Cited 0 times in

Cited 36 times in

TGF-beta Inhibitors for Therapeutic Management of Kidney Fibrosis

DC Field Value Language
dc.contributor.authorPark, Cheol Ho-
dc.contributor.authorYoo, Tae Hyun-
dc.date.accessioned2023-03-03T02:47:49Z-
dc.date.available2023-03-03T02:47:49Z-
dc.date.created2023-01-19-
dc.date.issued2022-11-
dc.identifier.issn1424-8247-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/192898-
dc.description.abstractKidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-beta 1 (TGF-beta 1) is the major factor driving fibrosis. TGF-beta 1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-beta 1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-beta 1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-beta 1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-beta 1 inhibitors in CKD management.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfPharmaceuticals-
dc.relation.isPartOfPHARMACEUTICALS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleTGF-beta Inhibitors for Therapeutic Management of Kidney Fibrosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorPark, Cheol Ho-
dc.contributor.googleauthorYoo, Tae Hyun-
dc.identifier.doi10.3390/ph15121485-
dc.relation.journalcodeJ04088-
dc.identifier.pmid36558936-
dc.subject.keywordTGF-beta-
dc.subject.keywordkidney-
dc.subject.keywordfibrosis-
dc.contributor.alternativeNameYoo, Tae Hyun-
dc.contributor.affiliatedAuthorPark, Cheol Ho-
dc.contributor.affiliatedAuthorYoo, Tae Hyun-
dc.identifier.scopusid2-s2.0-85144724658-
dc.identifier.wosid000904420000001-
dc.citation.volume15-
dc.citation.number12-
dc.identifier.bibliographicCitationPharmaceuticals, Vol.15(12), 2022-11-
dc.identifier.rimsid76798-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorTGF-beta-
dc.subject.keywordAuthorkidney-
dc.subject.keywordAuthorfibrosis-
dc.subject.keywordPlusGROWTH-FACTOR-BETA-
dc.subject.keywordPlusBONE MORPHOGENETIC PROTEIN-7-
dc.subject.keywordPlusHUMAN OSTEOGENIC PROTEIN-1-
dc.subject.keywordPlusTUBULE EPITHELIAL-CELLS-
dc.subject.keywordPlusPROMOTES RENAL FIBROSIS-
dc.subject.keywordPlusTRANSFORMING GROWTH-FACTOR-BETA-1-
dc.subject.keywordPlusDIABETIC-NEPHROPATHY-
dc.subject.keywordPlusMESENCHYMAL TRANSITION-
dc.subject.keywordPlusDIRECT PHOSPHORYLATION-
dc.subject.keywordPlusMOLECULAR-MECHANISMS-
dc.type.docTypeReview-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.identifier.articleno1485-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Show simple item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links